Package Leaflet: Information for the Patient
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 20 mg/5 mg/12,5 mg Film-Coated Tablets
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg/5 mg/12,5 mg Film-Coated Tablets
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg/10 mg/12,5 mg Film-Coated Tablets
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg/5 mg/25 mg Film-Coated Tablets
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg/10 mg/25 mg Film-Coated Tablets
Olmesartán medoxomilo / Amlodipino / Hidroclorotiazida
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1. What isOlmesartán/Amlodipino/Hidroclorotiazida Kern Pharmaand what it is used for
2. What you need to know before starting to takeOlmesartán/Amlodipino/Hidroclorotiazida Kern Pharma
3. How to takeOlmesartán/Amlodipino/Hidroclorotiazida Kern Pharma
4. Possible side effects
5. Storage ofOlmesartán/Amlodipino/Hidroclorotiazida Kern Pharma
6. Contents of the pack and additional information
This medication contains three active substances called olmesartan medoxomilo, amlodipine (as amlodipine besylate) and hydrochlorothiazide. The three substances help control high blood pressure.
The action of these substances contributes to lowering blood pressure. Olmesartan/hydrochlorothiazide/amlodipine is used to treat high blood pressure:
Do not take Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma
Inform your doctor before taking this medication if you think you may be allergic.
Do not take olmesartán/amlodipino/hidroclorotiazida if any of these cases occur.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma:
Tell your doctorif you are taking any of the following medications used to treat high blood pressure (hypertension):
Your doctor may need to monitor your kidney function, blood pressure, and electrolyte levels in your blood (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma”.
Tell your doctorif you have any of the following health problems:
Contact your doctor if you experience any of the following symptoms:
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after takingOlmesartán/Amlodipino/Hidroclorotiazida. Your doctor will decide whether to continue treatment. Do not stop takingOlmesartán/Amlodipino/Hidroclorotiazidain monotherapy.
Like any other medication that lowers blood pressure, excessive lowering of blood pressure in patients with alterations in blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will closely monitor your blood pressure.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma may cause an increase in lipid and uric acid levels in your blood. Your doctor may want to perform blood tests from time to time to monitor these possible changes.
Changes in blood levels of certain chemicals called electrolytes may occur. Your doctor may want to perform blood tests from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, slow, tired, drowsy, or restless, nausea, vomiting, decreased need to urinate, rapid heart rate.Tell your doctor if you notice any of these symptoms.
If you are scheduled to have parathyroid function tests, stop taking this medication before the tests are performed.
It is reported to athletes that this medication contains a component that may establish a positive analytical result for doping control.
Inform your doctor if you are pregnant (or think you may be). Do not take olmesartán/amlodipino/hidroclorotiazida at the beginning of pregnancy, and do not take it if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period (see section “Pregnancy and breastfeeding”).
Children and adolescents (under 18 years)
Olmesartán/amlodipino/hidroclorotiazida is not recommended for use in children and adolescents under 18 years.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any of the following medications:
Your doctor may need to adjust your dose and/or take other precautions:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any of the following medications for:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma with food and beverages
Olmesartán/amlodipino/hidroclorotiazida can be taken with or without food.
People taking olmesartán/amlodipino/hidroclorotiazida should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice may cause an increase in the blood levels of the active ingredient amlodipino, which may cause an unpredictable increase in the effect of lowering blood pressure of olmesartán/amlodipino/hidroclorotiazida.
Be careful when drinking alcohol while taking olmesartán/amlodipino/hidroclorotiazida, as some people may feel dizzy, nauseous, or experience headaches. If this happens, do not drink any alcohol.
Older patients
If you are over 65 years old, your doctor will regularly monitor your blood pressure every time you increase your dose, to ensure that your blood pressure does not drop too low.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant, or if you think you may be. Your doctor will advise you to stop taking olmesartán/amlodipino/hidroclorotiazida before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medication instead of olmesartán/amlodipino/hidroclorotiazida. Do not take olmesartán/amlodipino/hidroclorotiazida during pregnancy, and do not take it if you are more than 3 months pregnant, as it may cause serious harm to your baby if used from the third month of pregnancy.
If you become pregnant while taking olmesartán/amlodipino/hidroclorotiazida, inform and visit your doctor immediately.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. It has been shown that amlodipino and hidroclorotiazida pass into breast milk in small amounts. Do not take olmesartán/amlodipino/hidroclorotiazida while breastfeeding, and your doctor may choose another treatment if you wish to breastfeed.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
You may feel drowsy, nauseous, or experience headaches while taking medication for high blood pressure. If this happens, do not drive or operate machinery until the symptoms have disappeared. Consult your doctor.
This medication contains less than23 mg of sodium (1mmol)per coated tablet; this is, essentially “sodium-free”.
If you take more Olmesartan/Amlodipino/Hidroclorotiazida Kern Pharma than you should
If you take more tablets than you should, you will probably experience a drop in blood pressure, accompanied by symptoms such as dizziness, and a rapid or slow heart rate.
If you take more tablets than you should or if a child accidentally ingests some tablets, contact your doctor immediately or go to the nearest emergency center and bring the medication packaging or this leaflet with you.
Excess fluid may accumulate in the lungs (pulmonary edema) causing breathing difficulties that may develop up to 24-48 hours after ingestion.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20.
If you forgot to take Olmesartan/Amlodipino/Hidroclorotiazida Kern Pharma
If you forgot to take a dose, take the usual dose the next day. Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Olmesartan/Amlodipino/Hidroclorotiazida Kern Pharma
It is essential to continue taking this medication, unless your doctor tells you to stop treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. If they occur, they are often mild and do not require interrupting treatment.
The following side effects can be serious, although they affect only a small group of people:
During treatment with olmesartan/amlodipine/hydrochlorothiazide, allergic reactions with inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and skin rash can occur.If this happens, stop taking this medicine and consult your doctor immediately..
Olmesartan/amlodipine/hydrochlorothiazide can cause a pronounced drop in blood pressure in susceptible patients. This can cause severe dizziness or fainting.If this happens, stop taking this medicine, consult your doctor immediately, and remain lying down in a horizontal position.
Unknown frequency: If you experience yellowing of the white of the eyes, dark urine, skin itching, even if you started treatment withOlmesartan/amlodipine/hydrochlorothiazidesome time ago,contact your doctor immediatelywho will evaluate your symptoms and decide how to continue treatment for high blood pressure.
Olmesartan/amlodipine/hydrochlorothiazide is a combination of three active substances. The following information, first, describes the side effects reported so far with the combination olmesartan/amlodipine/hydrochlorothiazide (in addition to those already mentioned) and, second, the known side effects of each of the active substances separately, or when two of the substances are taken together.
To give you an idea of the number of patients who may experience side effects, they have been classified as frequent, infrequent, rare, and very rare.
These are other side effects known so far with olmesartan/amlodipine/hydrochlorothiazide:
If these side effects occur, they are often mild and it is not necessary to interrupt treatment.
Frequent(can affect up to 1 in 10 people)
Upper respiratory tract infection, sore throat, and nose, urinary tract infection, dizziness, headache, perception of heartbeats, low blood pressure, nausea, diarrhea, constipation, cramps, joint swelling, sensation of urgency to urinate, weakness, ankle swelling, fatigue, abnormal laboratory test results.
Infrequent(can affect up to 1 in 100 people)
Dizziness when getting up, vertigo, rapid heartbeat, sensation of fainting, flushing and sensation of heat in the face, cough, dry mouth, muscle weakness, inability to have or maintain an erection.
Rare(can affect up to 1 in 1,000 people)
Intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea
These are the side effects known for each of the active substances separately or when two of the substances are taken together:
They can be side effects due to olmesartan/amlodipine/hydrochlorothiazide, even if they have not been observed so far with olmesartan/amlodipine/hydrochlorothiazide.
Very frequent(can affect more than 1 in 10 people)
Edema (fluid retention).
Frequent(can affect up to 1 in 10 people)
Bronchitis, stomach and intestine infection, vomiting, increased blood sugar, sugar in urine, confusion, drowsiness, visual disturbances (including double vision and blurred vision), nasal secretion or congestion, sore throat, difficulty breathing, cough, abdominal pain, stomach burning, stomach discomfort, flatulence, joint or bone pain, back pain, bone pain, blood in urine, flu-like symptoms, chest pain, pain.
Infrequent(can affect up to 1 in 100 people)
Reduced number of a type of blood cell, called platelets, which can cause easy bruising or prolong bleeding time, anaphylactic reactions, abnormal decrease in appetite (anorexia), sleep problems, irritability, mood changes including anxiety, sensation of depression, chills, sleep disorders, alteration of taste, loss of consciousness, decreased sense of touch, sensation of numbness, worsening of myopia, ringing in the ears (tinnitus), angina (chest pain or discomfort known as angina pectoris), irregular heartbeat, rash, hair loss, allergic skin inflammation, skin redness, purple patches or spots on the skin due to small hemorrhages (purpura), skin discoloration, red itchy patches (urticaria), increased sweating, pruritus, skin rash, skin reactions to light, such as sunburn or skin eruption, muscle pain, urination problems, sensation of needing to urinate at night, breast enlargement in men, decreased libido, swelling of the face, sensation of discomfort, weight gain or loss, fatigue.
Rare(can affect up to 1 in 1,000 people)
Salivary gland inflammation and pain, decreased number of white blood cells in the blood, which could increase the risk of infections, decreased number of red blood cells (anemia), bone marrow damage, restlessness, sensation of loss of interest (apathy), seizures (convulsions), yellowish perception of objects when looking at them, dry eyes, blood clots (thrombosis, embolism), fluid accumulation in the lungs, pneumonia, inflammation of blood vessels and small blood vessels in the skin, pancreatitis, yellowish discoloration of the skin and eyes, acute inflammation of the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain, and cold hands and fingers, severe skin reactions including intense skin eruption, urticaria, skin redness, severe itching, blisters, peeling, and skin inflammation, Stevens-Johnson syndrome, toxic epidermal necrolysis, sometimes very severe, movement impairment, acute kidney failure, non-infectious kidney inflammation, decreased kidney function, fever.
Intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea
Very rare(can affect up to 1 in 10,000 people)
High muscle tension, numbness of hands or feet, heart attack, stomach inflammation, gum thickening, intestinal obstruction, liver inflammation, acute respiratory distress (signs include severe difficulty breathing, fever, weakness, and confusion).
Unknown frequency(cannot be estimated from available data)
Decreased vision or eye pain [possible signs of fluid accumulation in the vascular layer of the eye (choroidal hemorrhage) or acute angle-closure glaucoma]. Tremors, rigid posture, mask-like face, slow movements, and unsteady gait dragging the feet.
Skin and lip cancer (non-melanoma skin cancer).
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and blister after “CAD.” The expiration date is the last day of the month indicated.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 20 mg/5 mg/12.5 mg
Store below 30°C.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg/5 mg/12.5 mg, 40 mg/5 mg/25 mg, 40 mg/10 mg/12.5 mg, 40 mg/10 mg/25 mg:
This medication does not require special storage conditions.
Medicines should not be thrown away through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 20 mg /5 mg/12,5 mg: Each film-coated tablet contains 20 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besylate) and 12.5 mg of hydrochlorothiazide.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /5 mg/12,5 mg: Each film-coated tablet contains 40 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besylate) and 12.5 mg of hydrochlorothiazide.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /10 mg/12,5 mg: Each film-coated tablet contains 40 mg of olmesartan medoxomil, 10 mg of amlodipine (as amlodipine besylate) and 12.5 mg of hydrochlorothiazide.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /5 mg/25 mg: Each film-coated tablet contains 40 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besylate) and 25 mg of hydrochlorothiazide.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /10 mg/25 mg: Each film-coated tablet contains 40 mg of olmesartan medoxomil, 10 mg of amlodipine (as amlodipine besylate) and 25 mg of hydrochlorothiazide.
Tablet core: Maize pregelatinised starch, microcrystalline cellulose silicified, (microcrystalline cellulose with colloidal anhydrous silica), croscarmellose sodium and magnesium stearate.
Tablet coating: Poly(vinyl alcohol), macrogol, talc, titanium dioxide (E-171), yellow iron oxide (E-172), red iron oxide (E-172) (tablets of 20 mg/5 mg/12,5 mg, 40 mg/10 mg/12,5 mg, 40 mg/10 mg/25 mg) and black iron oxide (E-172) (tablets of 20 mg/5 mg/12,5 mg, 40 mg/10 mg/12,5 mg, 40 mg/10 mg/25 mg).
Appearance of the product and contents of the package:
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 20 mg /5 mg/12,5 mg:film-coated tablets, round and light brown in color.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /5 mg/12,5 mg:film-coated tablets, round and yellow in color.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /10 mg/12,5 mg:film-coated tablets, round and pink in color.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /5 mg/25 mg:film-coated tablets, oblong and yellow in color.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma 40 mg /10 mg/25 mg:film-coated tablets, oblong and pink in color.
Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma film-coated tablets are presented in packages containing blister packs ofAl/Al of 28 film-coated tablets and a clinical pack of 500 film-coated tablets.
Marketing Authorization Holder
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa - Barcelona
Spain
Responsible for manufacturing
LACER S.A.
Boters, 5 - Parc Tecnològic del Vallès
08290 Cerdanyola del Vallès - Barcelona
Spain
Last review date of this leaflet: February 2025
Other sources of information
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.